BioXcel Therapeutics (BTAI) director granted 17,000 stock options

Rhea-AI Filing Summary

BioXcel Therapeutics director Michal Votruba received a grant of 17,000 stock options on January 9, 2026. These options give the right to purchase 17,000 shares of BioXcel Therapeutics common stock and expire on January 9, 2036. The grant is structured so that the options vest and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the next annual meeting of stockholders after the grant date, provided Votruba continues to serve as a non-employee director through that vesting date. After this grant, Votruba beneficially owns 17,000 derivative securities in the form of these options, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Votruba Michal

(Last) (First) (Middle)

C/O BIOXCEL THERAPEUTICS, INC.

555 LONG WHARF DRIVE, 12TH FLOOR

(Street)

NEW HAVEN CT 06511

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioXcel Therapeutics, Inc. [ BTAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.01	01/09/2026		A		17,000		(1)	01/09/2036	Common Stock	17,000	$0	17,000	D

Explanation of Responses:

1. The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.

	/s/ Richard Steinhart, Attorney-in-Fact for Michal Votruba	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioXcel Therapeutics (BTAI) report for Michal Votruba?

BioXcel Therapeutics reported that director Michal Votruba was granted 17,000 stock options on January 9, 2026, giving him the right to buy 17,000 shares of the company’s common stock.

How many BioXcel Therapeutics stock options does Michal Votruba own after this Form 4 filing?

Following the reported transaction, Michal Votruba beneficially owns 17,000 stock options related to BioXcel Therapeutics common stock, all held in direct ownership form.

When do Michal Votruba’s BioXcel Therapeutics stock options vest?

The options will vest and become exercisable on the earlier of (i) the first anniversary of the January 9, 2026 grant date or (ii) the day immediately prior to the date of the next annual meeting of stockholders occurring after that grant date, subject to his continued service as a non-employee director.

What is the expiration date of Michal Votruba’s BioXcel Therapeutics stock options?

The reported stock options granted to Michal Votruba have an expiration date of January 9, 2036, as disclosed in the derivative securities table.

What role does Michal Votruba hold at BioXcel Therapeutics according to the Form 4?

According to the filing, Michal Votruba is a director of BioXcel Therapeutics and is not listed as an officer or 10% owner in this Form 4.

Is the reported BioXcel Therapeutics Form 4 transaction a grant or a sale of securities?

The Form 4 discloses an acquisition of derivative securities, specifically a grant of 17,000 stock options to director Michal Votruba, rather than a sale of existing shares.